Arrowhead Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Arrowhead Pharmaceuticals is a biopharmaceutical company. The company focuses on treatments for Hepatitis B, the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease.
Arrowhead Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Arrowhead Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Arrowhead Pharmaceuticals cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Arrowhead Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Arrowhead Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Arrowhead Pharmaceuticals assets
Arrowhead Pharmaceuticals cash flows

Arrowhead Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
ARWR:USArrowhead Pharmaceuticals, Inc.Common share-US04280A1007$27.21
Arrowhead Pharmaceuticals news
11.05.2022
Arrowhead Pharmaceuticals reported a GAAP loss of $18.506 million for 6 months of fiscal year 2022, down 2.5 times from $47.55 million in the previous year. Revenue increased 2.3 times to $179.244 million from $54.113 million a year earlier.
03.02.2022
The loss of Arrowhead Pharmaceuticals under GAAP for 3 months of fiscal year 2022 was $62.87 million, a 3-fold increase from $20.732 million in the previous year. Revenue increased 28.8% to $27.439 million from $21.303 million a year earlier.
23.11.2021
Arrowhead Pharmaceuticals' GAAP loss for fiscal year 2021 was $140.848 million, up 66.6% from $84.553 million in the prior year. Revenue increased 57.2% to $138.287 million compared to $87.992 million a year earlier.
06.08.2021
Arrowhead Pharmaceuticals reported a GAAP loss of $77.474 million for 9 months of fiscal year 2021, up 2.1 times from $36.12 million in the prior year. Revenue increased 24.4% to $100.004 million from $80.359 million a year earlier.
General information
Company nameArrowhead Pharmaceuticals
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address225 SOUTH LAKE AVENUE SUITE 1050 PASADENA CA 91101 626-304-3400
Mailing address225 SOUTH LAKE AVENUE SUITE 1050 PASADENA CA 91101
Websitewww.arrowheadpharma.com
Information disclosurewww.sec.gov